Breadcrumb

What's New at the RI-MUHC ?

Novel gene therapy trial offers hope to patients with rare metabolic disease

Samuel is the first Canadian and the ninth patient worldwide to participate in the second phase of a study using gene...

Call for Applications: Executive Director and Chief Scientific Officer, Research Institute of the McGill University Health Centre (RI-MUHC)

The RI-MUHC is seeking a dynamic and strategic leader to serve as its next Executive Director and Chief Scientific Officer (ED/CSO)

Interdisciplinary Consortium Receives Grant to Develop Next-Generation Cell-Based Cancer Vaccines

Cell-based cancer vaccines are revolutionizing the treatment of previously incurable cancers

COVID-19 pandemic: Looking back to better tackle future challenges

In two recent studies, RI-MUHC researchers provide useful information for evaluating public health strategies

Canadian researchers work together to develop made-in-Canada COVID-19 testing capacity

The road towards Canadian testing capacity began in Montreal

Rifampin for Latent TB: Shorter and safer than the standard treatment, but also cheaper

A new study shows that rifampin regimen is cheaper than isoniazid for latent tuberculosis

COVID-19 pandemic: the need for privacy and digital contact tracing

RI-MUHC researcher Abhinav Sharma calls for an approach emphasizing voluntary consent

COVID-19 impact on cancer patients: MUHC researchers take part in a multinational study

Published in The Lancet, the study reveals cancer-specific factors associated with increased mortality

Why do some non-smokers get COPD while many heavy smokers don’t?

A new study highlights a strong risk factor for COPD related to lung development

Hydroxychloroquine not effective in preventing the development of COVID-19 when used as post-exposure prophylaxis

A new study suggests that hydroxychloroquine is not effective in preventing the development of COVID-19 in individuals exposed to SARS-CoV-2

Learn more about the RI-MUHC